Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. - Wikidata - wikimedia - TriplyDB

Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.

Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.

http://www.wikidata.org/entity/Q35214746

about

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics A perspective on the structure and receptor binding properties of immunoglobulin G Fc Targeting the Fc receptor in autoimmune disease Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life Targeting FcRn for the modulation of antibody dynamics The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy Modern Technologies for Creating Synthetic Antibodies for Clinical application.The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics.Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice.Engineered clearing agents for the selective depletion of antigen-specific antibodies Clinical ramifications of the MHC family Fc receptor FcRn.Characterization and screening of IgG binding to the neonatal Fc receptor.Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model.Polymeric human Fc-fusion proteins with modified effector functions.Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.The immunologic functions of the neonatal Fc receptor for IgG An engineered selenocysteine defines a unique class of antibody derivatives.Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice.Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments.Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.Inhibitors of the FcRn:IgG protein-protein interaction.Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions.The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy.Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys.Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues.Commentary: "There's been a Flaw in Our Thinking".Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions.Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.

P2860

Q26822421-24B2B14A-30CE-4A79-9880-F3BC2B678AB4 Q26827579-01C449EE-4A91-4C93-A377-1DF37B5D480C Q27002843-66AD3138-C8F5-4C90-999D-8BEBBABD6515 Q27027238-6BD74A2B-637A-467A-B530-18788BF4274A Q28079016-59021AB2-FDC6-439B-8264-BD70F4005E9C Q28080589-DBCFBFA2-2B3B-4D94-B88E-E151FDE68653 Q28257521-59D7ECC1-262B-4DC6-AFDA-872925EBBA2A Q30467308-0B33FF21-EAB2-42D5-B15F-07FB5086815D Q30566003-49AD341F-43B9-4E7A-9EDF-C8A00C3F1631 Q33573587-7D7127B4-E41A-4817-907D-78CCA61BF7C7 Q33758483-F4EB6B63-FE62-4F15-8CD5-441E224DB1E2 Q33766669-D9C49B03-EA8E-490C-9C0B-2A90D8B562DF Q34754673-D142804E-B367-459A-AB54-E35007902680 Q35163945-64BC6B71-3062-4220-9257-05C1FCED682B Q35170050-6FEA33FE-2867-44EB-B1B7-FE00BD771418 Q35551564-0ACDAEBE-394D-41A0-853A-D8AB2D3178CE Q35899107-F1CD929A-117F-4290-B08D-9DEF956D5DEC Q36080399-DD57D933-FB34-4B79-92AE-D42BDDF627AB Q36211427-F87B006B-2E48-4E46-85FB-46A1CD9E3106 Q36542347-30A98DD0-4D11-4D34-9DB9-DBF1248CC0D8 Q36843553-031784CF-EB6E-4745-AADB-ECB0DE263617 Q37115251-D39C58A2-F131-4B3B-89A9-5375105E093A Q37334251-1E4F9D3A-47D2-4CF3-BDD3-9730119F1FC3 Q37364343-95403227-7835-4EEE-BDE7-E8868D28E15F Q37508794-2DCDC80F-32E9-4921-BEF7-70893E0DCC36 Q37597698-2A4974AB-6861-43BD-A25F-80B6D7DD90E5 Q37698914-B05F84FE-D381-4CD6-AD50-591D524A64D7 Q37798387-44B7928D-9015-4A4A-83CB-5A79A268BD21 Q37986126-FF0F23B4-4E31-4A39-94D2-B80A65D817EE Q37998314-B5368B0C-71B5-423D-9C77-68BB3A3EACD8 Q38718049-D8213B2F-30A8-471A-8C60-F213EFD3946F Q38821056-7FC0DF59-8665-48A0-8718-3827E69FDDAD Q38883267-F0DFDC42-7C06-4098-9BB3-489B4E625AD8 Q39388182-5476635F-AE62-498D-B835-9E983B44F085 Q39540318-C8FE2143-E606-4581-AAAB-8F91268D291A Q39959699-1663DF2F-CA61-4C8E-81B6-C1A21C790D33 Q41704150-DA682A76-EFCF-4C4E-871F-334074F77D68 Q41931879-DE197DBD-BB66-4337-B3DD-75A62EE7AAD3 Q42173120-C3C67AAE-5221-437B-BA86-85E765E0D504 Q42557601-4CA05466-8F28-417B-B991-2962B9987A3A

P2860

Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.

http://www.wikidata.org/entity/Q35214746

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Divergent activities of an eng ...... ns for therapeutic antibodies.

@ast

Divergent activities of an eng ...... ns for therapeutic antibodies.

@en

type

label

Divergent activities of an eng ...... ns for therapeutic antibodies.

@ast

Divergent activities of an eng ...... ns for therapeutic antibodies.

@en

prefLabel

Divergent activities of an eng ...... ns for therapeutic antibodies.

@ast

Divergent activities of an eng ...... ns for therapeutic antibodies.

@en

P1433

Q35214746-8487C451-AFE2-4DBE-B3B7-DE247B339281

P1476

Q35214746-D2C04DBD-6E2D-4BA5-8F97-A66B8C53889D

P2093

Q35214746-415FB900-6A49-4A1E-9338-F04981627D5B

Q35214746-7BC1F875-633B-4DDA-A093-E32A5BF4EE4D

Q35214746-8A56907D-EC80-4ADE-800F-D807B2DA7EC6

Q35214746-8D6D1A64-8AFB-4570-ADBE-A9974F5122AD

Q35214746-8DD9B34C-0321-4877-9F04-F2E2D2658704

P2860

Q35214746-000E8381-117B-480A-8E2D-889638DD4919

Q35214746-04135043-B5B1-44FF-91CE-AC33675ADB59

Q35214746-10A63BE4-437B-4D41-B66F-8C11E72ECEE8

Q35214746-160F6F72-FDB4-4C1B-B054-618D5E464FEB

Q35214746-19FA1CAA-AAC8-495E-A088-A10BE3EE290B

Q35214746-1B01CAA9-21D9-4728-8195-F6F870A91133

Q35214746-31801357-370E-4BC2-9E5D-A9A6C4D18CAC

Q35214746-3DEC0904-54A4-466C-A6C0-4573D0AC0276

Q35214746-4300F9A7-9309-4BA5-9242-07FEC4784067

Q35214746-46117F52-C311-4125-8D47-33DFD0107916

P304

Q35214746-F5DC6537-DA38-407B-8A5B-8EEF762B6DCE

P31

Q35214746-83D75BB2-1B17-4B5E-B5F0-35EEC1E37995

P356

Q35214746-DE54C5AD-6F2B-4FAA-A8CA-BB4B0AF7BCDA

P407

Q35214746-94CE52E9-88CB-4D43-A126-BB0C10318636

P433

Q35214746-00CA1116-AB4A-4418-9334-937F6EDF6B35

P478

Q35214746-B0D61B08-AC14-4BC4-91AB-9212A860481C

P577

Q35214746-89F2D3AB-9015-4026-A0DE-F8869F296EE8

P5875

Q35214746-1AACF55D-88C6-4B94-98D5-A1C3E37E07A5

P698

Q35214746-931E425F-680C-4285-B864-66E4142E92D4

P921

Q35214746-E58905A2-6839-4833-B80E-0871EC0ADE13

P932

Q35214746-A79C36A7-8D5B-408D-93D4-9490A9DA5651

P356

PNAS.0606304103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Divergent activities of an eng ...... ns for therapeutic antibodies.

@en

P2093

Carlos Vaccaro

http://www.w3.org/2001/XMLSchema#string

E Sally Ward

http://www.w3.org/2001/XMLSchema#string

Raimund J Ober

http://www.w3.org/2001/XMLSchema#string

Roger Bawdon

http://www.w3.org/2001/XMLSchema#string

Sylvia Wanjie

http://www.w3.org/2001/XMLSchema#string

P2860

A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus

MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells

Functional reconstitution of human FcRn in Madin-Darby canine kidney cells requires co-expressed human beta 2-microglobulin

Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding

Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution

The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans

pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat.

Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level.

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line

P304

18709-18714

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0606304103

http://www.w3.org/2001/XMLSchema#string

P407

P433

49

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6680854

http://www.w3.org/2001/XMLSchema#string

P698

17116867

http://www.w3.org/2001/XMLSchema#string

P921

P932

1693727

http://www.w3.org/2001/XMLSchema#string